RxDoctor Payments Data

Douglas Williams, OD

Optometrist · Pittsford, NYNPI 1457386138

Payments from drug & device makers

$959in general payments, 2019–2025

Across 37 payments — averaging $25.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$234
  • Alcon$160
  • Coopervision Inc.$117
  • Sight Sciences, Inc.$114
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$83
  • Shire North American Group Inc$73
  • plus $178 from 7 others

What the payments were for

  • Speaking & faculty fees$263%
  • Food & beverage$93497%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$959 in reported general payments places this provider in the 60th percentile of 2,743 optometrist providers in New York.

See all optometrist providers in New York

Medicare billing

Part B allowed, 2024
$22,534
Medicare patients
162
Services billed
211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost23$13,179
Brimonidine Tartrate98$8,602
SimbrinzaBrinzolamide/Brimonidine Tart22$4,929
Travoprost21$4,829
Timolol Maleate130$4,170
Latanoprost219$2,669
Brinzolamide11$2,289
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$1,343
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat43$596
Prednisolone Acetate13$539
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha30$346
Dorzolamide Hcl12$191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$47$13,17923 claims
AlconSimbrinza$160$4,92922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,743 optometrist providers in New York.

Other optometrist in Pittsford

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →